Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2015

01.06.2015

Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery

verfasst von: Sigrun Dahl, Jon Håvard Loge, Viktor Berge, Alv Andreas Dahl, Milada Cvancarova, Sophie Dorothea Fosså

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to study the influence of radical prostatectomy (RP) for prostate cancer on work status and working life in men 3 years after surgery.

Methods

In a prospective, questionnaire-based study on adverse effects after RP, 330 prostate cancer (PCa) patients who had been active in the workforce before RP described their work status 3 years after having surgery. We dichotomized their postoperative work status into “unchanged or increased” versus “reduced.” The participants also reported whether their working life was influenced by the PCa trajectory to no, some, or a great extent. Univariate and multiple logistic regression models were established with sociodemographic and clinical characteristics as independent variables and “work status” or “influence of PCa trajectory on working life” as dependent variables.

Results

Twenty-five percent of the participants had retired. Of the remaining participants, approximately 20 % had a reduced work status, which in the multivariate analyses was significantly associated with increasing age. One third of the men still active in the workforce considered the PCa to negatively influence their working life. This was independently associated with bother related to urinary leakage, fatigue, and having undergone additional oncological therapy (pelvic radiotherapy and/or hormone treatment).

Conclusion

Though RP does not affect work status in most men, approximately one third of them experience problems in their working life due to adverse effects related to RP and/or additional post-RP anti-cancer therapy.

Implications for Cancer Survivors

Most PCa survivors can expect to remain in the workforce for at least 3 years after RP, but for some, persistent adverse effects after RP and /or additional anti-cancer treatment negatively affect their working life. Pre-RP counseling of men within the workforce should cover possible post-RP changes concerning work status and working life.
Literatur
1.
Zurück zum Zitat Amir Z, Moran T, Walsh L, Iddenden R, Luker K. Return to paid work after cancer: a British experience. J Cancer Surviv. 2007;1(2):129–36.CrossRefPubMed Amir Z, Moran T, Walsh L, Iddenden R, Luker K. Return to paid work after cancer: a British experience. J Cancer Surviv. 2007;1(2):129–36.CrossRefPubMed
2.
Zurück zum Zitat Spelten ER, Verbeek JHAM, Uitterhoeve ALJ, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work—a prospective cohort study. Eur J Cancer. 2003;39(11):1562–7.CrossRefPubMed Spelten ER, Verbeek JHAM, Uitterhoeve ALJ, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work—a prospective cohort study. Eur J Cancer. 2003;39(11):1562–7.CrossRefPubMed
4.
Zurück zum Zitat Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.CrossRefPubMed Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.CrossRefPubMed
5.
Zurück zum Zitat Stensvold A, Dahl AA, Brennhovd B, Smastuen MC, Fossa SD, Lilleby W, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol 2012 Feb 16 Stensvold A, Dahl AA, Brennhovd B, Smastuen MC, Fossa SD, Lilleby W, et al. Bother problems in prostate cancer patients after curative treatment. Urol Oncol 2012 Feb 16
6.
Zurück zum Zitat Dahl S, Steinsvik EA, Dahl AA, Loge JH, Cvancarova M, Fossa SD. Return to work and sick leave after radical prostatectomy: a prospective clinical study. Acta Oncol 2013 Nov 6. Dahl S, Steinsvik EA, Dahl AA, Loge JH, Cvancarova M, Fossa SD. Return to work and sick leave after radical prostatectomy: a prospective clinical study. Acta Oncol 2013 Nov 6.
7.
Zurück zum Zitat Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fossa SD. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int. 2012;109(9):1366–74.CrossRefPubMed Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fossa SD. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int. 2012;109(9):1366–74.CrossRefPubMed
8.
Zurück zum Zitat Ilmarinen J, Tuomi K, Klockars M. Changes in the work ability of active employees over an 11-year period. Scand J Work Environ Health. 1997;23 Suppl 1:49–57.PubMed Ilmarinen J, Tuomi K, Klockars M. Changes in the work ability of active employees over an 11-year period. Scand J Work Environ Health. 1997;23 Suppl 1:49–57.PubMed
9.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed
10.
Zurück zum Zitat Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.CrossRefPubMed Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.CrossRefPubMed
11.
Zurück zum Zitat Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMed Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMed
12.
Zurück zum Zitat Statistics Norway. Levekårsundersøkelsen 2002. 2014. Ref Type: Unpublished Work Statistics Norway. Levekårsundersøkelsen 2002. 2014. Ref Type: Unpublished Work
13.
Zurück zum Zitat Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. Int Qual Life Assess J Clin Epidemiol. 1998;51(11):1171–8. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. Int Qual Life Assess J Clin Epidemiol. 1998;51(11):1171–8.
14.
Zurück zum Zitat Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–53.CrossRefPubMed Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–53.CrossRefPubMed
15.
Zurück zum Zitat Nordby P, Nerland SM, Næsheim H. Yrkesaktivitet blant eldre før og etter pensjonsreformen. Statistics Norway 2014 Nordby P, Nerland SM, Næsheim H. Yrkesaktivitet blant eldre før og etter pensjonsreformen. Statistics Norway 2014
16.
Zurück zum Zitat Wold M.G, Håland I. Eldre i arbeidslivet. Statistics Norway 2014 Wold M.G, Håland I. Eldre i arbeidslivet. Statistics Norway 2014
17.
Zurück zum Zitat Bradley CJ, Neumark D, Luo Z, Bednarek H, Schenk M. Employment outcomes of men treated for prostate cancer. J Natl Cancer Inst. 2005;97(13):958–65.CrossRefPubMed Bradley CJ, Neumark D, Luo Z, Bednarek H, Schenk M. Employment outcomes of men treated for prostate cancer. J Natl Cancer Inst. 2005;97(13):958–65.CrossRefPubMed
18.
Zurück zum Zitat Bradley CJ, Neumark D, Luo Z, Schenk M. Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Invest. 2007;25(1):47–54.CrossRefPubMed Bradley CJ, Neumark D, Luo Z, Schenk M. Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Invest. 2007;25(1):47–54.CrossRefPubMed
19.
Zurück zum Zitat Oberst K, Bradley CJ, Gardiner JC, Schenk M, Given CW. Work task disability in employed breast and prostate cancer patients. J Cancer Surviv Res Pract. 2010;4(4):322–30.CrossRef Oberst K, Bradley CJ, Gardiner JC, Schenk M, Given CW. Work task disability in employed breast and prostate cancer patients. J Cancer Surviv Res Pract. 2010;4(4):322–30.CrossRef
20.
Zurück zum Zitat Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology. 2009;18(12):1252–60.CrossRefPubMed Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV. Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology. 2009;18(12):1252–60.CrossRefPubMed
21.
Zurück zum Zitat Torp S, Nielsen RA, Gudbergsson SB, Fossa SD, Dahl AA. Sick leave patterns among 5-year cancer survivors: a registry-based retrospective cohort study. J Cancer Surviv. 2012;6(3):315–23.CrossRefPubMed Torp S, Nielsen RA, Gudbergsson SB, Fossa SD, Dahl AA. Sick leave patterns among 5-year cancer survivors: a registry-based retrospective cohort study. J Cancer Surviv. 2012;6(3):315–23.CrossRefPubMed
22.
Zurück zum Zitat Maunsell E, Drolet M, Brisson J, Brisson C, Masse B, Deschenes L. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst. 2004;96(24):1813–22.CrossRefPubMed Maunsell E, Drolet M, Brisson J, Brisson C, Masse B, Deschenes L. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst. 2004;96(24):1813–22.CrossRefPubMed
23.
Zurück zum Zitat Duijts S, Egmond M, Spelten E, van Muijen P, Anema J, van der Beek A. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psycho-Oncology. 2013;22:327–8. Duijts S, Egmond M, Spelten E, van Muijen P, Anema J, van der Beek A. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psycho-Oncology. 2013;22:327–8.
24.
Zurück zum Zitat Gore JL, Gollapudi K, Bergman J, Kwan L, Krupski TL, Litwin MS. Correlates of bother following treatment for clinically localized prostate cancer. J Urol. 2010;184(4):1309–15.CrossRefPubMed Gore JL, Gollapudi K, Bergman J, Kwan L, Krupski TL, Litwin MS. Correlates of bother following treatment for clinically localized prostate cancer. J Urol. 2010;184(4):1309–15.CrossRefPubMed
25.
Zurück zum Zitat Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619–28.PubMed Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19(6):1619–28.PubMed
26.
Zurück zum Zitat Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 2014 Feb 7. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 2014 Feb 7.
27.
Zurück zum Zitat Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.CrossRefPubMed Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.CrossRefPubMed
28.
Zurück zum Zitat Grunfeld EA, Drudge-Coates L, Rixon L, Eaton E, Cooper AF. “The only way I know how to live is to work”: a qualitative study of work following treatment for prostate cancer. Health Psychol. 2013;32(1):75–82.CrossRefPubMed Grunfeld EA, Drudge-Coates L, Rixon L, Eaton E, Cooper AF. “The only way I know how to live is to work”: a qualitative study of work following treatment for prostate cancer. Health Psychol. 2013;32(1):75–82.CrossRefPubMed
29.
Zurück zum Zitat Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–91.PubMed Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–91.PubMed
30.
Zurück zum Zitat Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fossa SD. Fatigue in hormone-naive prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis. 2010;13(2):144–50.CrossRefPubMed Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fossa SD. Fatigue in hormone-naive prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis. 2010;13(2):144–50.CrossRefPubMed
31.
Zurück zum Zitat Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate. 2010;70(13):1480–9.CrossRefPubMed Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate. 2010;70(13):1480–9.CrossRefPubMed
32.
Zurück zum Zitat Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer. 2013;21(6):1761–71.CrossRefPubMed Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer. 2013;21(6):1761–71.CrossRefPubMed
33.
Zurück zum Zitat Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77(2):109–30.CrossRefPubMed Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77(2):109–30.CrossRefPubMed
34.
Zurück zum Zitat Iversen P, Mcleod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–81.CrossRefPubMed Iversen P, Mcleod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–81.CrossRefPubMed
Metadaten
Titel
Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery
verfasst von
Sigrun Dahl
Jon Håvard Loge
Viktor Berge
Alv Andreas Dahl
Milada Cvancarova
Sophie Dorothea Fosså
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2015
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0399-6

Weitere Artikel der Ausgabe 2/2015

Journal of Cancer Survivorship 2/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.